Jove
Visualize
Contact Us

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
154
Skin Cancer01:30

Skin Cancer

4.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Nivolumab Plus Relatlimab In Advanced Melanoma: Relativity-047 4-year Update.
  1. Home
  3. Nivolumab Plus Relatlimab In Advanced Melanoma: Relativity-047 4-year Update.

Related Experiment Video

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.

Evan J Lipson1, F Stephen Hodi2, Hussein Tawbi3

  • 1The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

European Journal of Cancer (Oxford, England : 1990)
|June 13, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Nivolumab plus relatlimab showed durable progression-free survival benefits in advanced melanoma patients after four years. This combination therapy offers improved outcomes with a lower toxicity profile compared to nivolumab alone.

Keywords:
Advanced melanomaImmunotherapyLong-term survivalNivolumabRelatlimab

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

Related Experiment Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

Area of Science:

  • Oncology
  • Immunotherapy
  • Melanoma Research

Background:

  • Advanced melanoma presents a significant challenge in treatment.
  • Nivolumab plus relatlimab is an investigational immunotherapy combination.
  • Previous studies indicated potential benefits of this combination.

Purpose of the Study:

  • To present updated 4-year efficacy and safety data from the RELATIVITY-047 trial.
  • To evaluate the long-term outcomes of nivolumab plus relatlimab versus nivolumab monotherapy in advanced melanoma.

Main Methods:

  • Phase 2/3 randomized trial (RELATIVITY-047).
  • Patients received nivolumab 480 mg plus relatlimab 160 mg fixed-dose combination or nivolumab 480 mg intravenously every 4 weeks.
  • Primary endpoint: progression-free survival (PFS) by blinded independent central review (BICR).
  • Secondary endpoints included overall survival (OS) and melanoma-specific survival (MSS).

    • Main Results:

    • Four-year PFS rates were 30.6% for the combination versus 23.6% for nivolumab alone.
    • Four-year OS rates were 52.0% for the combination versus 42.8% for nivolumab.
    • Objective response rate (ORR) was 43.9% for the combination versus 33.4% for nivolumab.
    • Four-year MSS rates were 59.7% for the combination versus 49.6% for nivolumab.
    • Efficacy favored the combination across most subgroups with no new safety signals.

    Conclusions:

    • Nivolumab plus relatlimab demonstrated a durable improvement in PFS, OS, and ORR in previously untreated advanced melanoma patients after 4 years.
    • The combination therapy offers a favorable benefit-risk profile with lower toxicity compared to other immuno-oncology combinations.
    • Long-term data support nivolumab plus relatlimab as a valuable treatment option for advanced melanoma.